Boston Scientific Corp. reports $5.14 billion revenue for quarter ended September 30, 2026, up 1.4%

ยท BSX

Boston Scientific Corp. reported revenue of $5.14 billion for the quarter ended September 30, 2026, an increase of 1.4% from the same quarter a year earlier ($5.07 billion).

For the same period it posted net income of $580 million, down 23.2%, or $0.40 per diluted share (0.51 a year earlier).

That is a net margin of 11.3%.

On Sanad's AAOIFI Standard 21 screen, Boston Scientific Corp. is currently compliant: interest-bearing debt is 19.2% of market capitalisation (limit 30%), and impure income is 0.5% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 2, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Boston Scientific Corp. news